-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 10, Thyda Bio initiated a single-dose administration Phase I clinical study of the new drug IBI112 in healthy subjects on the Drug Clinical Trial Registration and Information Disclosure Platform.
the main purpose of the study was to evaluate the safety and tolerance of Chinese healthy subjects after a single dose of off-the-cortective injection or intravenous injection to IBI112.
secondary purpose was to evaluate the characteristics and immunogenicity of post-drug pharmacological dynamics (PK) of IBI112 in a single dose of subderfic injection or intravenous giving to healthy subjects in China.
purpose of the study was to evaluate the post-IBI112 pharmacodynamic (PD) characteristics of single-dose subderfect injections or intravenous giving to healthy subjects in China.
IBI112 is an IL-23 monoantigen, IL-23 is a new type of isogenic cytokine consisting of il-12/IL-23p40 and specific IL-23p19 sub-base.
-23 play an important role in autoimmune diseases, rheumatoid arthritis and inflammatory bowel diseases and infections.
.